Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ph-1 Double-Blind Randomized Control Study-Evaluate Safety & Immunogenicity of Wanxing Bio-Pharmaceuticals AMA-1/MSP-1 Recombinant Malaria Vaccine (PfCP-2.9) Adj. w/ Montanide ISA 720 Compared to Montanide ISA 720 Alone in Adult Volunteers

NCT00284973 is registered in ClinicalTrials.gov with Shanghai Wanxing Bio-Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT00284973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00284973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ph-1 Double-Blind Randomized Control Study-Evaluate Safety & Immunogenicity of Wanxing Bio-Pharmaceuticals AMA-1/MSP-1 Recombinant Malaria Vaccine (PfCP-2.9) Adj. w/ Montanide ISA 720 Compared to Montanide ISA 720 Alone in Adult Volunteers
Lead sponsor
Shanghai Wanxing Bio-Pharmaceutical Co. Ltd.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2006
Completion date
Not reported
Enrollment
70
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prophylaxis against plasmodium falciparum malaria